Selling pharmaceuticals ethically in resource-limited settings: the case of Sofosbuvir View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-07-20

AUTHORS

Carl H. Coleman, Calvin Wai Loon Ho

ABSTRACT

In countries without universal health insurance systems, is it ethically acceptable for pharmaceutical companies to sell their products only to the relatively small segment of the population that can afford private insurance coverage or to pay for medications out of pocket? Are there certain drugs that companies should be expected to sell in these economies even if they are unable to do so profitably? Within a human rights framework, this paper identifies these and related ethical challenges and proposes some responses. The paper begins by considering general ethical responsibilities that arise from commitment to the Universal Health Coverage initiative as a Sustainable Development Goal. It then discusses ethical responsibilities on the part of pharmaceutical companies as distinct from those of national governments or the broader international community. Some proposals follow for thinking through specific ethical challenges that arise when making decisions about whether, and on what terms, to introduce a new drug into a particular setting. Finally, the paper considers a number of these issues and responses in the context of the sale of sofosbuvir in the Asia-Pacific region. More... »

PAGES

87-101

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s41649-017-0014-z

DOI

http://dx.doi.org/10.1007/s41649-017-0014-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1090852282


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/22", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Philosophy and Religious Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2201", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Ethics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Seton Hall University School of Law, Newark, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.263379.a", 
          "name": [
            "Seton Hall University School of Law, Newark, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coleman", 
        "givenName": "Carl H.", 
        "id": "sg:person.01101255214.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101255214.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "WHO Collaborating Centre for Bioethics (Singapore), Singapore, Singapore", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore", 
            "WHO Collaborating Centre for Bioethics (Singapore), Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ho", 
        "givenName": "Calvin Wai Loon", 
        "id": "sg:person.07525633002.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07525633002.56"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1472-6963-10-153", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049104756", 
          "https://doi.org/10.1186/1472-6963-10-153"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-07-20", 
    "datePublishedReg": "2017-07-20", 
    "description": "In countries without universal health insurance systems, is it ethically acceptable for pharmaceutical companies to sell their products only to the relatively small segment of the population that can afford private insurance coverage or to pay for medications out of pocket? Are there certain drugs that companies should be expected to sell in these economies even if they are unable to do so profitably? Within a human rights framework, this paper identifies these and related ethical challenges and proposes some responses. The paper begins by considering general ethical responsibilities that arise from commitment to the Universal Health Coverage initiative as a Sustainable Development Goal. It then discusses ethical responsibilities on the part of pharmaceutical companies as distinct from those of national governments or the broader international community. Some proposals follow for thinking through specific ethical challenges that arise when making decisions about whether, and on what terms, to introduce a new drug into a particular setting. Finally, the paper considers a number of these issues and responses in the context of the sale of sofosbuvir in the Asia-Pacific region.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s41649-017-0014-z", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1048445", 
        "issn": [
          "1793-8759", 
          "1793-9453"
        ], 
        "name": "Asian Bioethics Review", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1-2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "9"
      }
    ], 
    "keywords": [
      "ethical challenges", 
      "ethical responsibility", 
      "related ethical challenges", 
      "specific ethical challenges", 
      "human rights framework", 
      "broader international community", 
      "Sustainable Development Goals", 
      "Asia-Pacific region", 
      "rights framework", 
      "national governments", 
      "international community", 
      "Development Goals", 
      "responsibility", 
      "particular setting", 
      "pharmaceutical companies", 
      "insurance system", 
      "health insurance system", 
      "commitment", 
      "government", 
      "universal health insurance system", 
      "economy", 
      "initiatives", 
      "challenges", 
      "companies", 
      "countries", 
      "community", 
      "issues", 
      "context", 
      "insurance coverage", 
      "proposal", 
      "private insurance coverage", 
      "framework", 
      "decisions", 
      "paper", 
      "goal", 
      "setting", 
      "part", 
      "sales", 
      "terms", 
      "coverage", 
      "population", 
      "small segment", 
      "region", 
      "response", 
      "cases", 
      "system", 
      "number", 
      "segments", 
      "certain drugs", 
      "products", 
      "pharmaceuticals", 
      "resource-limited settings", 
      "new drugs", 
      "pocket", 
      "drugs", 
      "medications", 
      "sofosbuvir"
    ], 
    "name": "Selling pharmaceuticals ethically in resource-limited settings: the case of Sofosbuvir", 
    "pagination": "87-101", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1090852282"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s41649-017-0014-z"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s41649-017-0014-z", 
      "https://app.dimensions.ai/details/publication/pub.1090852282"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_727.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s41649-017-0014-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s41649-017-0014-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s41649-017-0014-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s41649-017-0014-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s41649-017-0014-z'


 

This table displays all metadata directly associated to this object as RDF triples.

129 TRIPLES      21 PREDICATES      82 URIs      73 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s41649-017-0014-z schema:about anzsrc-for:22
2 anzsrc-for:2201
3 schema:author N8eb473348c954a52a08dbcb83987b022
4 schema:citation sg:pub.10.1186/1472-6963-10-153
5 schema:datePublished 2017-07-20
6 schema:datePublishedReg 2017-07-20
7 schema:description In countries without universal health insurance systems, is it ethically acceptable for pharmaceutical companies to sell their products only to the relatively small segment of the population that can afford private insurance coverage or to pay for medications out of pocket? Are there certain drugs that companies should be expected to sell in these economies even if they are unable to do so profitably? Within a human rights framework, this paper identifies these and related ethical challenges and proposes some responses. The paper begins by considering general ethical responsibilities that arise from commitment to the Universal Health Coverage initiative as a Sustainable Development Goal. It then discusses ethical responsibilities on the part of pharmaceutical companies as distinct from those of national governments or the broader international community. Some proposals follow for thinking through specific ethical challenges that arise when making decisions about whether, and on what terms, to introduce a new drug into a particular setting. Finally, the paper considers a number of these issues and responses in the context of the sale of sofosbuvir in the Asia-Pacific region.
8 schema:genre article
9 schema:isAccessibleForFree false
10 schema:isPartOf N3bac40ad2bb043e8bfd8093fb6929b56
11 N70a5795ff6c9484e80c5b9aa322bf595
12 sg:journal.1048445
13 schema:keywords Asia-Pacific region
14 Development Goals
15 Sustainable Development Goals
16 broader international community
17 cases
18 certain drugs
19 challenges
20 commitment
21 community
22 companies
23 context
24 countries
25 coverage
26 decisions
27 drugs
28 economy
29 ethical challenges
30 ethical responsibility
31 framework
32 goal
33 government
34 health insurance system
35 human rights framework
36 initiatives
37 insurance coverage
38 insurance system
39 international community
40 issues
41 medications
42 national governments
43 new drugs
44 number
45 paper
46 part
47 particular setting
48 pharmaceutical companies
49 pharmaceuticals
50 pocket
51 population
52 private insurance coverage
53 products
54 proposal
55 region
56 related ethical challenges
57 resource-limited settings
58 response
59 responsibility
60 rights framework
61 sales
62 segments
63 setting
64 small segment
65 sofosbuvir
66 specific ethical challenges
67 system
68 terms
69 universal health insurance system
70 schema:name Selling pharmaceuticals ethically in resource-limited settings: the case of Sofosbuvir
71 schema:pagination 87-101
72 schema:productId N18ea99eec05f4006be57094e5b3da980
73 N9a4411f6d15544af8386a86500c23111
74 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090852282
75 https://doi.org/10.1007/s41649-017-0014-z
76 schema:sdDatePublished 2022-12-01T06:35
77 schema:sdLicense https://scigraph.springernature.com/explorer/license/
78 schema:sdPublisher Nad2b6c44341c4c4b9502c49cf8fd1e47
79 schema:url https://doi.org/10.1007/s41649-017-0014-z
80 sgo:license sg:explorer/license/
81 sgo:sdDataset articles
82 rdf:type schema:ScholarlyArticle
83 N18ea99eec05f4006be57094e5b3da980 schema:name doi
84 schema:value 10.1007/s41649-017-0014-z
85 rdf:type schema:PropertyValue
86 N3bac40ad2bb043e8bfd8093fb6929b56 schema:volumeNumber 9
87 rdf:type schema:PublicationVolume
88 N70a5795ff6c9484e80c5b9aa322bf595 schema:issueNumber 1-2
89 rdf:type schema:PublicationIssue
90 N8eb473348c954a52a08dbcb83987b022 rdf:first sg:person.01101255214.37
91 rdf:rest Ndbba07193d464b88925f65c2a8d23b5e
92 N9a4411f6d15544af8386a86500c23111 schema:name dimensions_id
93 schema:value pub.1090852282
94 rdf:type schema:PropertyValue
95 Nad2b6c44341c4c4b9502c49cf8fd1e47 schema:name Springer Nature - SN SciGraph project
96 rdf:type schema:Organization
97 Ndbba07193d464b88925f65c2a8d23b5e rdf:first sg:person.07525633002.56
98 rdf:rest rdf:nil
99 anzsrc-for:22 schema:inDefinedTermSet anzsrc-for:
100 schema:name Philosophy and Religious Studies
101 rdf:type schema:DefinedTerm
102 anzsrc-for:2201 schema:inDefinedTermSet anzsrc-for:
103 schema:name Applied Ethics
104 rdf:type schema:DefinedTerm
105 sg:journal.1048445 schema:issn 1793-8759
106 1793-9453
107 schema:name Asian Bioethics Review
108 schema:publisher Springer Nature
109 rdf:type schema:Periodical
110 sg:person.01101255214.37 schema:affiliation grid-institutes:grid.263379.a
111 schema:familyName Coleman
112 schema:givenName Carl H.
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101255214.37
114 rdf:type schema:Person
115 sg:person.07525633002.56 schema:affiliation grid-institutes:None
116 schema:familyName Ho
117 schema:givenName Calvin Wai Loon
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07525633002.56
119 rdf:type schema:Person
120 sg:pub.10.1186/1472-6963-10-153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049104756
121 https://doi.org/10.1186/1472-6963-10-153
122 rdf:type schema:CreativeWork
123 grid-institutes:None schema:alternateName WHO Collaborating Centre for Bioethics (Singapore), Singapore, Singapore
124 schema:name Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
125 WHO Collaborating Centre for Bioethics (Singapore), Singapore, Singapore
126 rdf:type schema:Organization
127 grid-institutes:grid.263379.a schema:alternateName Seton Hall University School of Law, Newark, NJ, USA
128 schema:name Seton Hall University School of Law, Newark, NJ, USA
129 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...